Insider Cluster (2 insiders) ·Filed Sep 1, 2026

ANIP

ANI PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $609K total
Actionable Insight • Neutral

Insider sales at 0.04% of market cap are trivial and carry no bearish signal. The cluster is not actionable on its own. Monitor next 10-Q for any fundamental deterioration, but this filing does not warrant a trading response.

DirectionNeutral
Confidencemedium
Horizonimmediate
Latest settled — T+20d
ANIP ▼ -0.56% at T+20d
NEUTRAL call ✗ call lost -0.56% · α vs SPY -0.48% · entry $73.06 → $72.65
Next anchor: T+60d in 8w
Latest observation: T+21 +7.29% FF3 residual α
Entry anchored
Sep 1, 2026
via day open
T+1d
-1.46%
call -1.46% · α -2.51%
$71.99
settled 4w ago
T+5d
-2.19%
call -2.19% · α -1.23%
$71.46
settled 23d ago
T+20d
-0.56%
call -0.56% · α -0.48%
$72.65
settled 2d ago
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Two top ANIP executives—CEO Nikhil Lalwani and CFO Stephen Carey—collectively sold $609K in open-market shares within a week, representing ~0.04% of the $1.7B market cap. The dollar value is small relative to company size, and the historical calibration shows prior bullish-rated reports on ANIP have underperformed (avg T+20 alpha -2.95%). The cluster signals routine portfolio diversification rather than material negative information, consistent with the weak predictive power of insider sales clusters.

Key Financial Metrics

Direction
selling
Total Value
$609.0K
Insiders
2

Key Facts

  • CEO Lalwani sold 5.4K shares at ~$74.30 on 2026-08-25 ($401K)
  • CFO Carey sold 2.9K shares at ~$72.80 on 2026-08-31 ($207K)
  • Total cluster value $609K = ~0.036% of market cap (well below 0.1% threshold)
  • Both trades are open-market sales (code S)

Financial Impact

$609K total insider sales, insignificant relative to $1.7B market cap

Risk Factors

  • Over-interpretation of small, liquidity-driven insider sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ANIP-1788301176823
21 reports for ANIP
Performance horizon
43% Hit rate 3 of 7 directional calls best @ T+60▲ +8.88%Apr 8, 2026
Filters
Rows
Reports for ANIP — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$72.11 $77.91▲ +8.04%▲ +7.23%$71.97 (−0.19%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$73.06 $71.46▼ −2.19%▼ −1.23%$71.97 (−1.49%)
Aug 24, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$74.17 $73.25▼ −1.24%▼ −1.71%$71.97 (−2.97%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$74.77 $77.32▲ +3.41%▲ +5.37%$71.97 (−3.74%)
Aug 7, 2026
8w ago
8-K
BULLISH ★ 6/10
$78.25 $76.54▼ −2.19%▼ −2.58%$71.97 (−8.03%)
Jul 16, 2026
11w ago
Court Ruling
NEUTRAL ★ 2/10
$81.92 $78.53▼ −4.14%▼ −2.47%$71.97 (−12.15%)
Jul 13, 2026
11w ago
Press Release
BULLISH ★ 6/10
$81.08 $79.20▼ −2.32%▼ −1.53%$71.97 (−11.24%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$83.00 $82.94▼ −0.07%▲ +2.16%$71.97 (−13.29%)
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$81.65 $80.52▼ −1.38%▼ −1.82%$71.97 (−11.86%)
May 21, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$82.72 $76.71▼ −7.27%▼ −8.92%$71.97 (−13.00%)
Showing 10 of 21

US Market Status

Market Open — Closes in 2h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 1, 2026